Abstract: Objective  To investigate the predictive value of two methods of platelet function detection for VerifyNow and Multiplate in patients with acute coronary syndrome (ACS).Methods  Verify Now and Multiplate were used to detect the platelet reactivity of patients with ACS.   The relationship between platelet reactivity and major adverse cardiovascular events (MACE) was explored， including allcause death， non fatal myocardial infarction， non fatal stroke， stent thrombosis and revascularization. Results  After one year of followup for 120 patients with ACS， 18 patients (15%) had MACE. The platelet reactivity detected by the two methods was both associated with MACE. Logistic regression analysis found that only VerifyNow could predict the occurrence of MACE (P=0.01). VerifyNow detection showed that the incidence of MACE in patients with high platelet response (HPR) was 16%， and the incidence of MACE without HPR was 7% (OR=2.6， 95%CI=1.54.4，P=0.001). The incidence of MACE in patients with HPR was 13%， and the incidence of MACE without HPR was 9% (OR=1.5， 95%CI=0.92.5，P=0.11) without HPR. Conclusion  This study demonstrated VerifyNow could predict the adverse outcomes better in patients with ACS than Multiplate.

Key words: acute coronary syndrome, blood platelets